J. Goldman & Co’s Insmed INSM Stock Holding History

J. Goldman & Co’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-30,000	Closed	-$2.29M	–	542
2025 Q1	$2.29M	Buy	+30,000	New	+$2.29M	0.06%	279
2024 Q3	–	Sell	-13,500	Closed	-$905K	–	532
2024 Q2	$905K	Buy	+13,500	New	+$524K	0.03%	314
2019 Q4	–	Sell	-30,000	Closed	-$529K	–	308
2019 Q3	$529K	Buy	+30,000	New	+$579K	0.04%	223
2019 Q1	–	Sell	-130,000	Closed	-$1.71M	–	292
2018 Q4	$1.71M	Buy	+130,000	New	+$2.07M	0.13%	151
2015 Q2	–	Sell	-27,000	Closed	-$562K	–	279
2015 Q1	$562K	Buy	+27,000	New	+$476K	0.03%	247

Other funds holding INSM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

J. Goldman & Co's INSM Position: Q1 2026 in Review

J. Goldman & Co increased its Insmed (INSM) stake by 287% in Q1 2026, buying an estimated $632K and bringing the position to 5,545 shares worth $907K. The position accounts for 0.03% of the portfolio, ranked #436.

J. Goldman & Co first reported a position in INSM in Q4 2013 and has held it in 25 quarters since. The position peaked at $7.19M in Q4 2024. 669 funds tracked by Wall St. Rank hold INSM as of Q1 2026.

J. Goldman & Co held 5,545 shares of Insmed worth $907K as of Q1 2026.
J. Goldman & Co bought 4,114 Insmed shares in Q1 2026, an estimated $632K.
Insmed made up 0.03% of J. Goldman & Co's portfolio in Q1 2026, its #436 holding.
J. Goldman & Co first reported a position in Insmed in Q4 2013 and has held it in 25 quarters since.
J. Goldman & Co's Insmed position peaked at $7.19M in Q4 2024.
669 funds tracked by Wall St. Rank held Insmed as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.